Related Experiment Videos
Adjuvant postoperative radiation therapy for resectable rectal cancer
B D Minsky1, A M Cohen, W E Enker
1Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Radiation Medicine
|July 1, 1991
Summary
Pelvic radiation therapy with or without chemotherapy after rectal cancer surgery significantly reduces local failure rates. This treatment approach offers improved survival outcomes for patients with locally advanced rectal adenocarcinoma.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Rectal adenocarcinoma surgery has high local failure rates (15-65%) depending on stage.
- Local recurrence significantly impacts patient survival and quality of life.
- Adjuvant therapies are crucial for improving outcomes in resectable rectal cancer.
Purpose of the Study:
- To evaluate the impact of pelvic radiation therapy +/- chemotherapy on local failure.
- To assess the effect of this multimodal approach on survival in rectal cancer patients.
- To analyze patterns of failure and complications in a prospective cohort.
Main Methods:
- Prospective analysis of 25 patients treated with pelvic radiation therapy +/- chemotherapy.
- Median follow-up of 30 months (range: 10-48 months).
- Actuarial calculations for survival and local failure incidence.
Main Results:
- Overall 3-year actuarial survival was 74%.
- Actuarial incidence of local failure was 17% for the total group.
- For node-positive disease (T1-4N1-2), 3-year survival was 80% with 15% local failure.
Conclusions:
- Pelvic radiation therapy +/- chemotherapy is effective in reducing local failure after rectal cancer surgery.
- This approach demonstrates acceptable complication rates, including 8% small bowel obstruction requiring surgery.
- Multimodal therapy improves survival and local control for patients with rectal adenocarcinoma.